Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MiNK Therapeutics, Inc. - Common Stock
(NQ:
INKT
)
11.67
+0.21 (+1.83%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about MiNK Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
November 11, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
November 07, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
October 31, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Earnings Outlook For MiNK Therapeutics
↗
March 20, 2024
Via
Benzinga
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
October 08, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 04, 2024
Via
Benzinga
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
October 04, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
September 03, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024
↗
August 13, 2024
INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
MiNK Reports Second Quarter 2024 Results and Business Update
August 13, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
August 01, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
July 31, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
June 05, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
May 22, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024
↗
May 14, 2024
INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
MiNK Reports First Quarter 2024 Results
May 14, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Why MiNK Therapeutics Stock Is Up 11% Monday
↗
May 13, 2024
MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
May 13, 2024
Via
Benzinga
MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
May 13, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
April 30, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
↗
April 08, 2024
Via
Benzinga
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
April 08, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
April 05, 2024
Shares of Byrna Technologies Inc. (NASDAQ: BYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
April 05, 2024
Via
Benzinga
INKT Stock Earnings: MiNK Therapeutics Misses EPS for Q4 2023
↗
March 21, 2024
INKT stock results show that MiNK Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
MiNK Reports Fourth Quarter and Year-End 2023 Results
March 21, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
March 07, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
Earnings Scheduled For March 21, 2024
↗
March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million.
Via
Benzinga
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
March 06, 2024
MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model
From
MiNK Therapeutics
Via
GlobeNewswire
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
February 14, 2024
From
MiNK Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
